More Questions As Biocon Pulls EU Filings For Two Biosimilars
Executive Summary
Biocon and partner Mylan have withdrawn the European application for their biosimilar trastuzumab and pegfilgrastim in the backdrop of compliance blips at Biocon’s Indian site, raising critical questions on how soon things can be set right in an increasingly competitive scenario.
You may also be interested in...
Biocon, Dr Reddy’s Might Be Out Of The Woods On GMP Issue
Two Indian firms – Biocon and Dr Reddy’s – have received crucial establishment inspection reports (EIRs) from the US FDA amid improved compliance levels at their manufacturing sites.
Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo
The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.
Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo
The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.